Singaporean Biotech To Go Public Via $1.5B SPAC Merger
Singapore-based biotechnology company Nanyang Biologics Pte. Ltd. on Thursday announced plans to go public in the U.S. by merging with special purpose acquisition company RF Acquisition Corp. II in a deal...To view the full article, register now.
Already a subscriber? Click here to view full article